London: An antibody called "alirocumab" can significantly lower cholesterol levels in patients with an inherited disease associated with very high levels of low density lipoprotein cholesterol (LDL-C) or what is called "bad" cholesterol, new research has found.
The analysis involving more than 1,250 patients with the inherited disease heterozygous familial hypercholesterolemia showed that alirocumab rapidly lowered LDL-C to unprecedented levels and the reductions were maintained long term.
"Heterozygous familial hypercholesterolemia is an inherited disease associated with very high levels of LDL-C that can put patients at risk for cardiovascular disease," said principal investigator John JP Kastelein, professor at University of Amsterdam, the Netherlands.
"Alirocumab belongs to a new class of cholesterol-lowering monoclonal antibodies that works by preventing action of the PCSK9 protein, which in turn increases the number of LDL receptors and thus increases uptake of LDL-C from the circulation," Mr Kastelein noted.
Researchers assessed the benefits of adding the PCSK9 monoclonal antibody alirocumab to statins and other standard of care therapy, compared to standard of care therapy (including statins) and placebo.
"The results show that adding alirocumab to statins in patients with heterozygous familial hypercholesterolemia rapidly lowers LDL-C to unprecedented levels that are unreachable with statins alone, and that these reductions are maintained in the long term," Mr Kastelein pointed out.
The findings were presented at the recently concluded European Society of Cardiology Congress 2015 in London.
The analysis involving more than 1,250 patients with the inherited disease heterozygous familial hypercholesterolemia showed that alirocumab rapidly lowered LDL-C to unprecedented levels and the reductions were maintained long term.
"Heterozygous familial hypercholesterolemia is an inherited disease associated with very high levels of LDL-C that can put patients at risk for cardiovascular disease," said principal investigator John JP Kastelein, professor at University of Amsterdam, the Netherlands.
Researchers assessed the benefits of adding the PCSK9 monoclonal antibody alirocumab to statins and other standard of care therapy, compared to standard of care therapy (including statins) and placebo.
Advertisement
The findings were presented at the recently concluded European Society of Cardiology Congress 2015 in London.
Advertisement
COMMENTS
Advertisement
Is Black Salt Healthy? Expert Weighs In The Health Benefits Do You Just Eat The Egg Whites And Toss Out The Yolk? Cardiologist Explains Why This Is A Mistake Which Oil Is Best For Your Air Fryer? Expert Reveals 'Entire NEET Paper Solved In 45 Minutes Before Exam?': Top Court To Centre "Had God On My Side": Donald Trump Recounts Being Shot At During Rally 32 Dead In Bangladesh Unrest, Protesters Set Fire To State TV Headquarters Google Brings AI To US Broadcast Of Paris Olympics Video: Children Jump On E-Rickshaw, Chase Foreigners For Money In Delhi "Every Time I Try To Eat Healthy" - Video Creator's Editing Skills Amaze Internet Track Latest News Live on NDTV.com and get news updates from India and around the world.